Aktuellt
SENASTE
Redeye maintains its base case of SEK 265 per share after the news that Eisai has initiated a rolling submission for Biologics license application under the accelerated approval pathway - for lecanemab. We expected it, and based on the high quality clinical data from phase II, good safety and efficacy profile, we are positive to the outcome of this application.
LÄS MER
